ERBB2 and breast carcinoma: A second phase II clinical trial (VUBAR) is examining the relationship between image-based HER2 assessment following uptake of 68Ga-NOTA-2Rs15d in patients with local or distant breast cancer metastases and the outcomes of a biopsy of the same lesion [83].